AAL-<wbr/>993

AAL-993

CAT N°: 16351
Price:

From 109.00 92.65

AAL-993 is a potent inhibitor of VEGF receptors, inhibiting VEGFR1, 2, and 3 with IC50 values of 130, 23, and 18 nM, respectively.{26698,26700} It less potently inhibits c-Kit, colony stimulating factor 1 receptor, PGDF receptor ?, and EGF receptor (IC50s = 236, 380, 640, and 1,040 nM, respectively) and is without effect on a number of other tyrosine kinases.{26698} AAL-993 is orally bioavailable in vivo, blocks VEGF-induced angiogenesis, and prevents the growth of primary tumors and spontaneous peripheral metastases in mice.{26698,26699} It also inhibits hypoxia-mediated increase in hypoxia-inducible factor-1 transcriptional activity in an ERK-dependent manner (IC50 = ~5 µM).{26701}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-?[(4-?pyridinylmethyl)?amino]?-?N-?[3-?(trifluoromethyl)?phenyl]?-benzamide
  • Correlated keywords
    • inhibitors angiogenesis cancers signals transductions hypoxia receptors biochemistry inhibits inhibitions VEGF inhibiting VEGFR VEGFR-1 VEGFR1 VEGFR-2 VEGFR2 VEGFR-3 VEGFR3 1 2 3 one two three c-Kit c Kit colony stimulating factors PGDF ? EGF orally bioavailable in vivo blocks VEGF-induced induced prevents growths primary tumors spontaneous peripheral metastases mice hypoxia-mediated increases hypoxia-inducible factor-1 transcriptional activity ERK-dependent ERK dependents manners AAL993 AAL 993 ZK-260253 ZK 260253 potent
  • Product Overview:
    AAL-993 is a potent inhibitor of VEGF receptors, inhibiting VEGFR1, 2, and 3 with IC50 values of 130, 23, and 18 nM, respectively.{26698,26700} It less potently inhibits c-Kit, colony stimulating factor 1 receptor, PGDF receptor ?, and EGF receptor (IC50s = 236, 380, 640, and 1,040 nM, respectively) and is without effect on a number of other tyrosine kinases.{26698} AAL-993 is orally bioavailable in vivo, blocks VEGF-induced angiogenesis, and prevents the growth of primary tumors and spontaneous peripheral metastases in mice.{26698,26699} It also inhibits hypoxia-mediated increase in hypoxia-inducible factor-1 transcriptional activity in an ERK-dependent manner (IC50 = ~5 µM).{26701}

We also advise you